Skip to main content
ARGENICA THERAPEUTICS LIMITED logo

ARGENICA THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · AGN ISIN · AU0000150328 ASX Professional, scientific and technical activities
Open in API
Filings indexed 281 across all filing types
Latest filing 2026-05-25 Share Issue/Capital Cha…
Country AU Australia
Listing ASX AGN

About ARGENICA THERAPEUTICS LIMITED

https://argenica.com.au/

Argenica Therapeutics Limited is a clinical-stage company focused on developing novel neuroprotective therapeutics to minimize brain tissue death following acute neurological injury. The company's lead drug candidate, ARG-007, is a cationic arginine-rich peptide engineered to inhibit multiple cell death pathways. ARG-007 is being developed for applications in ischemic stroke, traumatic brain injury, and hypoxic-ischaemic encephalopathy. The therapeutic is designed for rapid administration by first responders, aiming to protect brain cells during the critical window following an injury. By addressing the neurodegenerative cascade, the company seeks to improve long-term clinical outcomes for patients suffering from stroke and other forms of brain trauma.

Recent filings

Filing Released Lang Actions
Release of Securities from Voluntary Escrow 1 page 157.0KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement titled “RELEASE OF SECURITIES FROM VOLUNTARY ESCROW.” It specifies that fully paid ordinary shares will be released from escrow under ASX Listing Rule 3.10A. This notification concerns the company’s share capital structure change (release of escrowed shares). It is not a financial report or regulatory filing announcement, nor is it director insider trading or dividend related. It aligns with the “Share Issue/Capital Change” category for announcements regarding capital structure changes (Code: SHA).
2026-05-25 English
IND Application Advanced With Successful Completion of Assay 4 pages 343.8KB
Regulatory Filings Classification · 78% confidence The document is an ASX announcement by Argenica Therapeutics reporting completion of an FDA-requested genotoxicity assay and progress on its IND application. It contains no financial statements, earnings metrics, board changes, or capital transactions. It is not an annual or quarterly report, audit, proxy, or other specific form; rather it is a general regulatory update to the market. As such, it best fits the fallback category for miscellaneous regulatory announcements (RNS).
2026-05-20 English
Clinical Advisory Committee Established to Advance Phase 2b 2 pages 256.9KB
Regulatory Filings Classification · 75% confidence The document is an ASX announcement presenting the establishment of a Clinical Advisory Committee for trial advancement. It is not a financial report, not an earnings release, nor a report publication notice, nor a management change at the board executive level. It is a general ASX regulatory announcement (press release) that does not fit any specialized category, so it defaults to Regulatory Filings (RNS).
2026-05-13 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 479.8KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'APPENDIX 4C – 31 MARCH 2026 QUARTERLY ACTIVITIES & CASHFLOW REPORT' for Argenica Therapeutics Limited. It provides a detailed quarterly update on the company's activities, including clinical trial progress, regulatory interactions, funding, and cash flow details. The document includes a consolidated statement of cash flows for the quarter ended 31 March 2026 and year-to-date figures, consistent with the requirements of ASX Listing Rule 4.7B. The presence of actual financial data, cash flow statements, and detailed operational commentary for a quarter indicates this is a comprehensive interim/quarterly financial report rather than a brief announcement or a regulatory filing. The document length (15,000 characters) and content depth further support classification as an Interim / Quarterly Report (IR).
2026-04-28 English
Investor Presentation - Ignite Conference 14 pages 2.4MB
Investor Presentation Classification · 95% confidence The document is explicitly titled “INVESTOR PRESENTATION” and consists of presentation slides including a disclaimer, slide numbers, graphics, pipeline overview, clinical data, trial design, and future catalysts presented at the “IGNITE CONFERENCE – APRIL 2026.” There are no formal financial statements, regulatory form references, or voting results. It matches the structure and content of an investor deck. Therefore, it should be classified as an Investor Presentation.
2026-04-15 English
Presentations at European Stroke Organisation Conference 2 pages 308.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Argenica Therapeutics Limited about the acceptance of two abstracts for presentation at the 2026 European Stroke Organisation Conference. It details the titles of the presentations, the presenters, and the significance of the selection. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no management changes, no capital or financing updates, and no legal proceedings. The document is a public announcement about upcoming scientific presentations, not a report or financial filing. It is a general regulatory announcement about company activities, best fitting the category of Regulatory Filings (RNS). The document length is short (3290 characters), and it is not a report publication announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2026-03-25 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.